<DOC>
	<DOCNO>NCT00352833</DOCNO>
	<brief_summary>Investigation outcome adjuvant treatment catumaxomab compare surgery alone patient curative resection gastric adenocarcinoma order gain detailed information primary safety , tolerability feasibility secondary relevant efficacy parameter .</brief_summary>
	<brief_title>Safety Efficacy Study With Catumaxomab Patients After Curative Resection Gastric Adenocarcinoma</brief_title>
	<detailed_description>A control , randomize , open-label , multi-center , parallel-group , Phase II study generate valid hypothesis safety efficacy issue patient primary confirm diagnosis gastric adenocarcinoma high risk disseminate tumor cell due serosal infiltration curative gastrectomy . Eligible patient centrally randomized IVRS operation one two study group 1:1 ratio : surgery plus catumaxomab surgery alone . Treatment catumaxomab consist initial dose 10 µg give intraoperatively intraperitoneal bolus day 0 four follow ascend dos ( 10-20-50-150 µg ) administer i.p.-infusion via provide indwelling catheter day 7 , 10 , 13 16 , respectively .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Signed date informed consent Patient primary diagnosis histologically confirm gastric adenocarcinoma ( include GE junction SiewertType 2 3 ) Intended curative gastrectomy ( ` enbloc´R0resection consider standard D2scheme ) Serosal infiltration ( T3/T4 , N+/ , M0 ) confirm immediate section histopathologic assessment surgery Karnofsky index &gt; = 70 Negative pregnancy blood test screen woman childbearing potential Presence distant metastasis Macroscopic microscopic residual tumor present surgery State pancreas resection thoracotomy Exposure prior cancer therapy plan adjuvant chemoor radiotherapy current gastric cancer Previous treatment nonhumanized mouse rat monoclonal antibody Known/suspected hypersensitivity catumaxomab similar antibody Any cancer disease cancer treatment within last 5 year Presence constant immunosuppressive therapy Inadequate renal function ( creatinine &gt; 1.5 x ULN ) Inadequate hepatic function ( AST ALT &gt; 2.5 x ULN bilirubin &gt; = 1.5 x ULN ) Platelets &lt; 75000 cells/mm³ ; absolute neutrophil count &lt; 1500 cells/mm³ Patient bowel obstruction within last 30 day Pregnant nursing woman , woman childbearing potential use effective contraceptive method study least contraceptive , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization condom ) Presence acute chronic systemic infection Any condition accord investigator result undue risk patient participate present study Patient employee involve study investigator involve institution include study sponsor Parallel participation another clinical trial previous participation study Treatment another investigational product study last 30 day prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>investigational drug</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>intraoperative</keyword>
	<keyword>intraperitoneal</keyword>
	<keyword>EpCAM-positive tumor</keyword>
</DOC>